New Strategies for the Treatment and Prevention of Primary Headache Disorders

Overview

Journal Nat Rev Neurol

Specialty Neurology

Date 2016 Oct 28

PMID 27786243

Citations 32

Authors

Nathaniel M Schuster

Alan M Rapoport

Affiliations

Soon will be listed here.

Abstract

The primary headache disorders, which include migraine, cluster headache and tension-type headache, are among the most common diseases and leading causes of disability worldwide. The available treatment options for primary headache disorders have unsatisfactory rates of efficacy, tolerability and patient adherence. In this Review, we discuss promising new approaches for the prevention of primary headache disorders, such as monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor, and small-molecule CGRP receptor antagonists. Neuromodulation approaches employing noninvasive or implantable devices also show promise for treating primary headache disorders. Noninvasive treatments, such as transcranial magnetic stimulation and transcutaneous peripheral nerve stimulation, are delivered by devices that patients can self-administer. Implantable devices targeting the occipital nerves, sphenopalatine ganglion or high cervical spinal cord are placed using percutaneous and/or surgical procedures, and are powered either wirelessly or by surgically implanted batteries. These new and emerging treatments have the potential to address unmet patient needs and reduce headache-associated disability.

Citing Articles

Gradient Rotating Magnetic Fields Impairing F-Actin-Related Gene CCDC150 to Inhibit Triple-Negative Breast Cancer Metastasis by Inactivating TGF-β1/SMAD3 Signaling Pathway.

Zhang G, Yu T, Chai X, Zhang S, Liu J, Zhou Y Research (Wash D C). 2024; 7:0320.

PMID: 38420580 PMC: 10900498. DOI: 10.34133/research.0320.

Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study.

Suliman R, Santos V, Al Qaisi I, Aldaher B, Al Fardan A, Al Barrawy H Neurol Int. 2024; 16(1):274-288.

PMID: 38392960 PMC: 10893254. DOI: 10.3390/neurolint16010019.

New management strategies for primary headache disorders: Insights from P4 medicine.

Zhang Y, Huang W, Pan S, Shan Z, Zhou Y, Gan Q Heliyon. 2023; 9(11):e22285.

PMID: 38053857 PMC: 10694333. DOI: 10.1016/j.heliyon.2023.e22285.

Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review.

Szok D, Csati A, Vecsei L, Tajti J Life (Basel). 2023; 13(3).

PMID: 36983822 PMC: 10056004. DOI: 10.3390/life13030665.

Gel-forming antagonist provides a lasting effect on CGRP-induced vasodilation.

Chang C, Cai Z, Hsu S Front Pharmacol. 2022; 13:1040951.

PMID: 36569288 PMC: 9772450. DOI: 10.3389/fphar.2022.1040951.

References

Goldstein D, Roon K, Offen W, Ramadan N, Phebus L, Johnson K . Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001; 358(9289):1230-4. DOI: 10.1016/s0140-6736(01)06347-4. View

Hepp Z, Dodick D, Varon S, Gillard P, Hansen R, Devine E . Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2014; 35(6):478-88. DOI: 10.1177/0333102414547138. View

Lambru G, Shanahan P, Watkins L, Matharu M . Occipital nerve stimulation in the treatment of medically intractable SUNCT and SUNA. Pain Physician. 2014; 17(1):29-41. View

Wolter T, Kiemen A, Kaube H . High cervical spinal cord stimulation for chronic cluster headache. Cephalalgia. 2011; 31(11):1170-80. DOI: 10.1177/0333102411412627. View

Martelletti P, Katsarava Z, Lampl C, Magis D, Bendtsen L, Negro A . Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain. 2014; 15:47. PMC: 4237793. DOI: 10.1186/1129-2377-15-47. View

Kori S, Kellerman D, Voloshko P, Haugen G . Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers. Clin Ther. 2012; 34(9):1920-8. DOI: 10.1016/j.clinthera.2012.08.001. View

Fontaine D, Vandersteen C, Magis D, Lanteri-Minet M . Neuromodulation in cluster headache. Adv Tech Stand Neurosurg. 2014; 42:3-21. DOI: 10.1007/978-3-319-09066-5_1. View

Grace P, Ramos K, Rodgers K, Wang X, Hutchinson M, Lewis M . Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelae. Neuroscience. 2014; 280:299-317. PMC: 4250379. DOI: 10.1016/j.neuroscience.2014.09.020. View

De Agostino R, Federspiel B, Cesnulis E, Sandor P . High-cervical spinal cord stimulation for medically intractable chronic migraine. Neuromodulation. 2014; 18(4):289-96. DOI: 10.1111/ner.12236. View

10.

Goldstein J, Smith T, Pugach N, Griesser J, Sebree T, Pierce M . A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012; 52(9):1402-10. DOI: 10.1111/j.1526-4610.2012.02198.x. View

11.

Olesen J, Diener H, Husstedt I, Goadsby P, Hall D, Meier U . Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350(11):1104-10. DOI: 10.1056/NEJMoa030505. View

12.

Holland P, Akerman S, Goadsby P . Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther. 2005; 315(3):1380-5. DOI: 10.1124/jpet.105.090951. View

13.

Grace P, Maier S, Watkins L . Opioid-induced central immune signaling: implications for opioid analgesia. Headache. 2015; 55(4):475-89. PMC: 4402135. DOI: 10.1111/head.12552. View

14.

Siegel S, ONeill C, Dube L, Kaldeway P, Morris R, Jackson D . A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res. 2007; 24(10):1919-26. DOI: 10.1007/s11095-007-9317-1. View

15.

Burns B, Watkins L, Goadsby P . Treatment of hemicrania continua by occipital nerve stimulation with a bion device: long-term follow-up of a crossover study. Lancet Neurol. 2008; 7(11):1001-12. DOI: 10.1016/S1474-4422(08)70217-5. View

16.

Sjaastad O, Bakketeig L . Cluster headache prevalence. Vågå study of headache epidemiology. Cephalalgia. 2003; 23(7):528-33. DOI: 10.1046/j.1468-2982.2003.00585.x. View

17.

Holland P, Akerman S, Goadsby P . Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci. 2006; 24(10):2825-33. DOI: 10.1111/j.1460-9568.2006.05168.x. View

18.

Cooper Z, Johnson K, Pavlicova M, Glass A, Vosburg S, Sullivan M . The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol. 2015; 21(4):895-903. PMC: 4644513. DOI: 10.1111/adb.12261. View

19.

Misra U, Kalita J, Bhoi S . High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebo-controlled study. J Neurol. 2013; 260(11):2793-801. DOI: 10.1007/s00415-013-7072-2. View

20.

Schoenen J, Roberta B, Magis D, Coppola G . Noninvasive neurostimulation methods for migraine therapy: The available evidence. Cephalalgia. 2016; 36(12):1170-1180. DOI: 10.1177/0333102416636022. View